Tim Anderson Analyst PerformanceAnalyst at National Bank FinancialTim Anderson is a stock analyst at National Bank Financial in the healthcare sector, covering 13 publicly traded companies. Over the past year, Tim Anderson has issued 17 stock ratings, including buy, hold, and sell recommendations. While full access to Tim Anderson's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Tim Anderson's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings46 Last 11 YearsBuy Recommendations45.45% 20 Buy RatingsCompanies Covered13 Unique Companies Ratings Distribution44RatingsDistribution of strong buy, buy, hold, and sell ratings by Tim Anderson.RatingPercentageCount Strong Buy0.0%0 ratings Buy45.5%20 ratings Hold38.6%17 ratings Sell15.9%7 ratingsOut of 44 total stock ratings issued by Tim Anderson at National Bank Financial, the majority (45.5%) have been Buy recommendations, followed by 38.6% Hold and 15.9% Sell.Best & Worst CallsBest Call0000.0%APGEAug 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%AARDMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ53.8% of companies on NASDAQ7 companiesNYSE46.2% of companies on NYSE6 companiesTim Anderson, an analyst at National Bank Financial, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare13 companies100.0%Tim Anderson of National Bank Financial specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY7 companies53.8%PHARMACEUTICALS6 companies46.2% Tim Anderson's Ratings History at National Bank Financial Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsBMYBristol Myers Squibb10/9/2026Lower Price Target$59.18$66.00$0.0000.00% ROIJNJJohnson & Johnson9/29/2026Reiterated Rating$272.16$278.00Neutral$0.0000.00% ROIJNJJohnson & Johnson7/10/2026Boost Price Target$256.34$263.00Neutral$0.0000.00% ROIBMYBristol Myers Squibb7/10/2026Lower Price Target$57.31$66.00Buy$0.0000.00% ROIMRKMerck & Co., Inc.6/30/2026Boost Price Target$128.34$141.00Buy$0.0000.00% ROIBMYBristol Myers Squibb4/9/2026Lower Price Target$59.33$67.00Buy$0.0000.00% ROIJNJJohnson & Johnson3/2/2026Reiterated Rating$248.61Neutral$0.0000.00% ROIJNJJohnson & Johnson1/22/2026Boost Price Target$219.45$221.00Neutral$0.0000.00% ROIREGNRegeneron Pharmaceuticals1/7/2026Upgrade$776.54$860.00Buy$0.0000.00% ROIPFEPfizer1/6/2026Initiated Coverage$25.44$25.00Neutral$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. BMYBristol Myers Squibb12/15/2025Upgrade$52.38$61.00Buy$0.0000.00% ROILLYEli Lilly and Company12/15/2025Lower Price Target$1,027.68$1,268.00Buy$0.0000.00% ROIMRKMerck & Co., Inc.12/15/2025Boost Price Target$100.33$120.00Buy$0.0000.00% ROIJNJJohnson & Johnson12/15/2025Boost Price Target$211.65$220.00Neutral$0.0000.00% ROILLYEli Lilly and Company12/1/2025Set Price Target$1,057.73$1,286.00$0.0000.00% ROIREGNRegeneron Pharmaceuticals10/29/2025Boost Price Target$654.48$627.00Underperform$0.0000.00% ROIJNJJohnson & Johnson10/15/2025Boost Price Target$190.88$204.00Neutral$0.0000.00% ROIPFEPfizer10/3/2025Boost Price Target$27.08$30.00Neutral$00.0000.00% ROIJNJJohnson & Johnson10/3/2025Boost Price Target$187.73$198.00Neutral$000.0000.00% ROIPFEPfizer10/1/2025Reiterated Rating$26.30$28.00Neutral$00.0000.00% ROIAMGNAmgen9/26/2025Boost Price Target$271.86$272.00Underperform$000.0000.00% ROIMTSRMetsera8/28/2025Boost Price Target$36.38$50.00Buy$0.0000.00% ROIAARDAardvark Therapeutics8/28/2025Lower Price Target$8.64$25.00Buy$0.0000.00% ROIAPGEApogee Therapeutics8/28/2025Boost Price Target$36.98$87.00Buy$000.0000.00% ROIPFEPfizer8/6/2025Boost Price Target$24.69$28.00Neutral$00.0000.00% ROIAMGNAmgen7/23/2025Boost Price Target$307.42$261.00Underperform$000.0000.00% ROIJNJJohnson & Johnson7/17/2025Boost Price Target$164.78$175.00Neutral$000.0000.00% ROIREGNRegeneron Pharmaceuticals4/17/2025Lower Price Target$549.28$547.00Underperform$000.0000.00% ROIJNJJohnson & Johnson4/10/2025Lower Price Target$149.02$159.00Neutral$000.0000.00% ROIAARDAardvark Therapeutics3/27/2025Boost Price Target$10.38$26.00Buy$0.0000.00% ROIAARDAardvark Therapeutics3/10/2025Initiated Coverage$10.13$22.00Buy$0.0000.00% ROIJNJJohnson & Johnson3/5/2025Boost Price Target$164.67$171.00Neutral$000.0000.00% ROIGILDGilead Sciences3/5/2025Boost Price Target$115.60$126.00Buy$000.0000.00% ROIAMGNAmgen3/5/2025Boost Price Target$315.78$294.00Underperform$000.0000.00% ROIABBVAbbVie3/4/2025Boost Price Target$213.05$223.00Neutral$000.0000.00% ROIMTSRMetsera2/25/2025Initiated Coverage$29.81$38.00Buy$0.0000.00% ROIMRNAModerna2/11/2025Lower Price Target$31.87$34.00Underperform$00.0000.00% ROIAMGNAmgen2/6/2025Boost Price Target$307.81$275.00Underperform$000.0000.00% ROIMRKMerck & Co., Inc.2/5/2025Lower Price Target$88.67$112.00Buy$000.0000.00% ROIJNJJohnson & Johnson1/23/2025Lower Price Target$145.39$159.00Neutral$000.0000.00% ROILouis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.Get the name and ticker of Louis Navellier's #1 AI stock freeJNJJohnson & Johnson1/17/2025Lower Price Target$147.26$160.00Neutral$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupWeiss RatingsUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
